BRAVO Study for Functional Dyspepsia (BD)
Functional dyspepsia is one of the commonest digestive disorders. The pathophysiology of functional dyspepsia is uncertain. Proton pump inhibitor (PPI) has been recommended as the first line treatment for functional dyspepsia. However, the results on effectiveness of PPI are conflicting and it has been suggested that PPI is only effective for acid-related symptoms.
The investigators plan to use a wireless pH monitoring system positioned at the junction of esophagus and stomach to evaluate the chronological relationship between acid exposure at this region and symptoms of dyspepsia as well as its impact on the efficacy of acid suppressive therapy in treatment of functional dyspepsia.
Functional dyspepsia patients
Prince of Wales Hospital, Hong Kong
- To evaluate the chronological relationship between acid exposure at squamo-columnar junction (SCJ) and dyspeptic symptom in different subtypes of functional dyspepsia
- To evaluate the relationship between acid exposure at squamo-columnar junction and dyspeptic symptom response to PPI
- To compare the efficacy of PPI and placebo in treating functional dyspepsia patients
Esomeprazole 20mg vs Placebo o.d.
Double-blind randomized placebo-controlled trial
Number of subjects: 130
Functional dyspepsia patients without concomitant gastroesophageal reflux disease (GERD)
Duration of study:
1 June 2010 - 30 May 2012
Proportion of patients who report positive response to adequate relief of dyspeptic symptoms at week 8
Dyspeptic symptom scores, symptom association probability of dyspeptic symptoms in relation to esophageal pH of less than 4 as measured at 1 cm above SCJ.
Number of visits: 2
Increased acid exposure at SCJ contributes to dyspeptic symptom and predicts treatment response to PPI in FD patients without concomitant GERD
Drug: Esomeprazole 20mg
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Diagnostic
|Official Title:||Role of Gastroesophageal Acid Reflux at Squamo-columnar Junction in Functional Dyspepsia|
- The primary outcome measure is the proportion of patients who report positive response to adequate relief of dyspeptic symptoms at week 8. [ Time Frame: Week 8 ]The proportion of patients who report positive response
- The secondary outcome measures include dyspeptic symptom scores, symptom association probability of dyspeptic symptoms in relation to esophageal pH of less than 4 as measured at 1 cm above SCJ. [ Time Frame: 1st visit and 8 weeks ]Dyspeptic symptom scores, symptom association probability of dyspeptic symptoms in relation to esophageal pH
|Study Start Date:||August 2011|
|Estimated Study Completion Date:||December 2017|
|Estimated Primary Completion Date:||December 2017 (Final data collection date for primary outcome measure)|
Placebo Comparator: Placebo
Identical looking placebo (once daily)
Identical looking placebo
Experimental: Esomeprazole 20mg daily
Esomeprazole 20mg daily Oral for 8 weeks
Drug: Esomeprazole 20mg
Oral Esomeprazole 20mg daily for 8 weeks
Other Name: Nexium
Hide Detailed Description
All patients will be invited to complete self-administered questionnaires for demographics and baseline symptom assessment
- Demographics: age, gender
- Screening of functional gastrointestinal disorder based on the Rome III questionnaires
- Functional dyspepsia symptom questionnaire: an 8-item dyspeptic symptom score questionnaire using 4-point (0-3) Likert scale based on recall of the past 7 days for assessment of epigastric pain, epigastric burning, belching, bloating, postprandial fullness, early satiation, nausea and vomiting. Functional dyspepsia will be further classified into epigastric pain syndrome (EPS) and postprandial distress syndrome (PDS) according to the Rome III definitions.
- Global dyspeptic symptom assessment: a dichotomous patient-reported scale in which they are asked to give a response of either "Yes" or "No" to the inquiry "Do you have adequate relief of dyspeptic symptom over the last 7 days?"
- GERD symptom questionnaire: Patients will also be asked to report the frequency of heartburn or acid regurgitation over the last 3 months. Patients with frequency of reflux symptoms of more than twice per month are deemed to have concomitant GERD and they will be excluded from the study.
- Psychological disorder: Patient Health Questionnaire (PHQ) will be used for screening of concomitant psychological disorder such as depression and generalized anxiety disorder.
Upper endoscopy and BRAVO pH capsule insertion:
Upper endoscopy will be arranged within 2 weeks of baseline assessment in order to exclude organic pathology such as peptic ulcer, esophagitis and neoplasm. The position and morphology of gastroesophageal junction is assessed during withdrawal of endoscope after deflation of stomach at end-expiratory of the patient in left lateral body position. The morphology of gastroesophageal junction will be graded according to the "flap valve" concept. In order to avoid the confounding effect of gross anatomical disruption of gastroesophageal junction on acid exposure at SCJ, patients with grade IV disruption of gastroesophageal junction, which refers to patulous hiatus with axial displacement of SCJ, will be excluded.
After completion of endoscopy examination, the BRAVO delivery system will be passed orally into esophagus in the same body position. The endoscope is then reintroduced to facilitate positioning of the delivery system under direct visualization. The BRAVO pH capsule will be placed at 1 cm proximal to SCJ for monitoring of acid exposure at SCJ.
Recording of esophageal pH profile and symptoms:
The wireless esophageal pH monitoring will last for 48 hours. During the study period, the patients will be instructed to engage in their usual daily activities. The patients will be given a diary documenting meals, sleeping and dyspeptic symptoms. The patient has to return the Bravo data recorder after 48 hours.
Randomization of treatment:
After completion of BRAVO pH monitoring, patients will be randomly assigned to either esomeprazole 20mg daily or identical looking placebo for 8 weeks. The random allocation sequence will be obtained from a computer-generated list of random numbers in blocks of 10. Concealed allocation is achieved by an independent staff who assigns treatments according to consecutive numbers in sealed envelopes. Study medications are dispensed as sealed packages in consecutive numbers. Medication adherence is measured by pill counts during final visit (V2).
The patients will report their individual dyspeptic symptoms on weekly basis using a self administered symptom questionnaire. At week 4 and week 8, they will need to give an additional rating on their overall symptom response using global symptom assessment. The patients are required to give a dichotomous response of either "yes" or "no" to the question stating "Do you have adequate relief of symptoms over the past 7 days?"
Please refer to this study by its ClinicalTrials.gov identifier: NCT01349413
|Contact: Justin CY Wu, MBChB(CUHK)||(852)email@example.com|
|Contact: Yawen YC Chan, M Phil||(852)firstname.lastname@example.org|
|Prince of Wales Hospital||Recruiting|
|Hong Kong, Hong Kong|
|Contact: Justin CY Wu, MBChB(CUHK) (852)26323476 email@example.com|
|Principal Investigator: Justin CY Wu, MBChB(CUHK)|
|Principal Investigator:||Justin CY Wu, MBChB(CUHK)||Chinese University of Hong Kong|